Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) January 19, 2026
Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid (CSF) July 7, 2025
Belay Diagnostics Receives NIH Award to Advance Multi-Omic CSF Assay for Brain Cancer Diagnosis May 9, 2025
Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management April 25, 2025
Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection March 25, 2025
